Andrew D. Zelenetz, MD, PhD, and Stephen J. Schuster, MD, on DLBCL: Results of the JULIET Trial

2017 ASH Annual Meeting
Tweet this page

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Stephen J. Schuster, MD, of the Abramson Cancer Center, University of Pennsylvania, discuss phase II findings on CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (Abstract 577).

Advertisement

Advertisement



Advertisement